- Details
- Francesco Soria discusses a study validating the IBCG scoring system for intermediate-risk bladder cancer. He explains the heterogeneity of this risk group and the need for better stratification. Soria describes the IBCG model, which uses five risk factors to divide patients into three subgroups. The study validates this model using a large European cohort, showing significant differences in recur...
|
- Details
- Naomi Haas discusses the PROSPER trial, a study exploring perioperative nivolumab in high-risk renal cell carcinoma (RCC). The trial, which included both clear cell and non-clear cell histologies, aimed to assess whether priming the immune system preoperatively could improve outcomes. Despite initial optimism, the trial did not show a significant improvement in recurrence-free survival. Dr. Haas h...
|
- Details
- Anjali Kapur discusses a cost analysis comparing oral Phenazopyridine (Pyridium) to intravesical lidocaine for pain control during Botox injections for overactive bladder. The study finds that using Pyridium is less costly, saving about $98 per visit and potentially $24 million annually if widely adopted. Dr. Kapur highlights the high prevalence of overactive bladder and the increasing use of Boto...
|
- Details
- David Crawford discusses advancements in advanced urothelial cancer treatment with Daniel Petrylak. Dr. Petrylak highlights the success of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, combined with pembrolizumab. This combination demonstrates significant improvements in response rates and survival compared to standard chemotherapy, with a 30% complete response rate and d...
|
- Details
- David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....
|
- Details
- Oliver Sartor discusses radiopharmaceuticals with Germo Gericke. Dr. Gericke emphasizes the potential of targeted radioligand therapies, particularly for advanced cancers. He explores various isotopes, including Lutetium, Terbium, and Actinium, highlighting Actinium's promise in preclinical studies. Dr. Gericke discusses ideal target characteristics and Ariceum's innovative approach of targeting i...
|
- Details
- Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Zach Klaassen interviews Constantinos Zamboglou about a study on PSMA-PET/CT-guided salvage radiotherapy for recurrent prostate cancer after surgery. Dr. Zamboglou presents findings from a comparative analysis of PSMA-PET-guided and non-PSMA-guided salvage radiotherapy, using data from the SAKK09/10 trial and a retrospective database. The study demonstrates improved short- and mid-term biochemical...
|
- Details
- Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
|
